[go: up one dir, main page]

NO991358D0 - Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes - Google Patents

Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes

Info

Publication number
NO991358D0
NO991358D0 NO991358A NO991358A NO991358D0 NO 991358 D0 NO991358 D0 NO 991358D0 NO 991358 A NO991358 A NO 991358A NO 991358 A NO991358 A NO 991358A NO 991358 D0 NO991358 D0 NO 991358D0
Authority
NO
Norway
Prior art keywords
diabetes
development
prevent
sibutramine
analogues
Prior art date
Application number
NO991358A
Other languages
English (en)
Other versions
NO991358L (no
Inventor
Clifford James Bailey
Robert Brian Jones
Helen Cristine Jackson
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO991358D0 publication Critical patent/NO991358D0/no
Publication of NO991358L publication Critical patent/NO991358L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
NO991358A 1996-09-21 1999-03-19 Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes NO991358L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
NO991358D0 true NO991358D0 (no) 1999-03-19
NO991358L NO991358L (no) 1999-03-19

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991358A NO991358L (no) 1996-09-21 1999-03-19 Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (no)
EP (1) EP0927028A1 (no)
JP (1) JP2001503737A (no)
KR (1) KR20000048501A (no)
CN (1) CN1237905A (no)
AU (1) AU724488B2 (no)
BG (1) BG64473B1 (no)
BR (1) BR9711517A (no)
CA (1) CA2266401C (no)
CZ (1) CZ93699A3 (no)
GB (1) GB9619757D0 (no)
HR (1) HRP970505A2 (no)
HU (1) HUP9904026A3 (no)
ID (1) ID18320A (no)
IL (1) IL128850A (no)
MY (1) MY116150A (no)
NO (1) NO991358L (no)
NZ (1) NZ334580A (no)
PL (1) PL332305A1 (no)
RU (1) RU2245709C2 (no)
SK (1) SK31999A3 (no)
TR (1) TR199900618T2 (no)
TW (1) TW580385B (no)
UA (1) UA64726C2 (no)
WO (1) WO1998011884A1 (no)
ZA (1) ZA978450B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
SK287038B6 (sk) * 1998-11-12 2009-10-07 Smithkline Beecham Plc Farmaceutický prostriedok na postupné uvoľňovanie 5-[4-[2-(N- metyl-N-(2-pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu a metformínu a spôsob jeho výroby
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AU2003264968B2 (en) * 2002-10-05 2006-03-16 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US7700128B2 (en) 2003-10-31 2010-04-20 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US9237864B2 (en) 2009-07-02 2016-01-19 Dexcom, Inc. Analyte sensors and methods of manufacturing same
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
ES2726807T3 (es) 2011-12-30 2019-10-09 Reviva Pharmaceuticals Inc Composiciones, síntesis y métodos de uso de derivados de 1-[1-fenil-ciclobutil]isobutilamina
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
CA2266401A1 (en) 1998-03-26
CZ93699A3 (cs) 1999-08-11
IL128850A (en) 2003-07-31
HUP9904026A3 (en) 2000-07-28
BG103277A (en) 2000-01-31
US6174925B1 (en) 2001-01-16
US20040077730A1 (en) 2004-04-22
SK31999A3 (en) 1999-12-10
JP2001503737A (ja) 2001-03-21
KR20000048501A (ko) 2000-07-25
BR9711517A (pt) 1999-08-24
GB9619757D0 (en) 1996-11-06
ZA978450B (en) 1999-03-19
AU724488B2 (en) 2000-09-21
US6617360B1 (en) 2003-09-09
HRP970505A2 (en) 1998-08-31
EP0927028A1 (en) 1999-07-07
CA2266401C (en) 2007-01-30
RU2245709C2 (ru) 2005-02-10
BG64473B1 (bg) 2005-04-30
UA64726C2 (uk) 2004-03-15
CN1237905A (zh) 1999-12-08
ID18320A (id) 1998-03-26
PL332305A1 (en) 1999-08-30
HUP9904026A2 (hu) 2000-05-28
WO1998011884A1 (en) 1998-03-26
TW580385B (en) 2004-03-21
TR199900618T2 (xx) 1999-06-21
NO991358L (no) 1999-03-19
MY116150A (en) 2003-11-28
AU4774097A (en) 1998-04-14
NZ334580A (en) 2000-09-29
IL128850A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
NO991358L (no) Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes
EE03832B1 (et) Heptapeptiidanaloogid
DE69739216D1 (de) Der Entwicklung von konditionierten Reflexen angepasstes System
NO952357L (no) Formulering av insulinanaloger
DE69817830D1 (de) Kieselsaürehaltige schwefel-vulkanisierbare kautschukmischung
NO960482L (no) Skosåle
DE69826158D1 (de) Inspektionsgerät für das Aussehen von Kapseln
KR970706248A (ko) 불화된 유기화합물 제조방법(the preparation of fluorinated organic compounds)
EP0996458A4 (en) SANDRAMYCIN ANALOG
DE59701512D1 (de) Mehrprozessor-zentraleinheit
NO20001847L (no) Ny anvendelse av forbindelser for anti-kløe-aktivitet
DK0808831T3 (da) Fluorerede vitamin D3-analoger
ID22437A (id) Unit bilah pengaduk
DE3878868D1 (de) Generator fuer periodische zeitsignale des fractaltyps.
NO972278D0 (no) Fluorerte vitamin D3-analoger
NO964376D0 (no) Skosåle
DE69626799D1 (de) Navigationseinheit
NO20005507D0 (no) Spylerenseapparat
DE59502683D1 (de) Satelliten-navigationsverfahren
ID22787A (id) Nitro-benzamida berguna sebagai zat anti - arritimia
KR980004719U (ko) 모니터의 미끄럼 방지구조
ITAQ970012A1 (it) Soluzione per risolvere definitivamente la sudorazione dei piedi
LV11350A (lv) Arsienas buvesanas panemiens
ES1040434Y (es) Casa desmontable de uso infantil
KR960033885U (ko) 자동차 앞유리의 부착구조

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application